Publications

May 2019

Manuscript

JNCCN

Flatiron-authored

May 2019

Manuscript

Clinical Pharmacology and Therapeutics

Flatiron-authored

May 2019

Abstract

ISPOR Annual Meeting

May 2019

Abstract

ISPOR Annual Meeting

May 2019

Abstract

ISPOR Annual Meeting

May 2019

Abstract

ISPOR Annual Meeting

May 2019

Abstract

ISPOR Annual Meeting

Flatiron-authored

May 2019

Abstract

ISPOR Annual Meeting

Flatiron-authored

Machine Learning Model for Cancer Biomarker Identification in Electronic Health Records

Ambwani G, Cohen A, Estévez M, Singh N, Adamson B, Nussbaum N, Birnbaum B

May 2019

Abstract

ISPOR Annual Meeting

Flatiron-authored

May 2019

Abstract

ISPOR Annual Meeting

Flatiron-authored

May 2019

Manuscript

Cancer Control

April 2019

Manuscript

Clinical Lung Cancer

April 2019

Abstract

European Lung Cancer Conference

April 2019

Abstract

European Lung Cancer Conference

Treatment characteristics of patients with locally advanced or metastatic non-small cell lung cancer receiving atezolizumab monotherapy in US clinical practice

Frueh M, Rahma OE, Pachynski RK, Mazieres J, Goldschmidt, Jr J, Ton TGN, Mhatre SK, Chuo C-Y, Martinalbo J, Davies J, Juergens R.

April 2019

Abstract

European Lung Cancer Conference

Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database

Singal G, Miller PG, Agarwala V, Li G, Kaushik G, Backenroth D, Gossai A, Frampton GM, Torres AZ, Lehnert E, Bourque D, O’Connell C, Bowser B, Caron T, Baydur E, Seidl-Rathkopf K, Ivanov I, Alpha-Cobb G, Guria A, He J, Frank S, Nunnally A, Bailey M, Jaskiw A, Feuchtbaum D, Nussbaum N, Abernethy AP, Miller VA.

April 2019

Manuscript

JAMA

Flatiron-authored

April 2019

Manuscript

Cancer Epidemiology

Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice

Parikh RB, Galsky MD, Gyawali B, Riaz F, Kaufmann T, Cohen AB, Adamson BJS, Gross CP, Meropol NJ, Mamtani R.

April 2019

Manuscript

The Oncologist

Flatiron-authored

April 2019

Abstract

AACR Annual Meeting

Flatiron-authored

April 2019

Abstract

AACR Annual Meeting

April 2019

Manuscript

Perspectives in Health Information Management

Implementing an Electronic End-of-Life Chemotherapy Utilization Measure

Kraut J, Mooney K, Sweetenham JW, Page RD, Adelson K, Agarwala V, Fessele KL, Hamrick HJ, Kaganman I, Martineau J, Abernethy AP, and Meropol NJ

March 2019

Manuscript

Journal of Oncology Practice

Flatiron-authored

An evaluation of the impact of missing deaths on overall survival analyses of advanced non–small cell lung cancer patients conducted in an electronic health records database

Carrigan, G, Whipple, S, Taylor, MD, Torres, AZ, Gossai, A, Arnieri, B, Tucker, M, Hofmeister, PP, Lambert, P, Griffith, SD, Capra, WB

March 2019

Manuscript

Pharmacoepidemiology & Drug Safety

Flatiron-authored

March 2019

Manuscript

Frontiers in Oncology

Flatiron-authored

Increased risk of brain metastases in ovarian cancer patients with BRCA mutations

Ratner E, Bala M, Louie-Gao M, Aydin E, Hazard S, Brastianos PK

March 2019

Manuscript

Gynecologic Oncology

February 2019

Manuscript

Future Oncology

Real-world trends in first-line checkpoint inhibitor use in advanced urothelial cell carcinoma

Parikh RB, Galsky MD, Baxi SS, Adamson B, Cohen AB, Feld E, Christodouleas JP, Boursi SB, Meropol NJ, Mamtani R

February 2019

Abstract

ASCO GU Symposium

Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma at the end of life: Insights from real-world practice

Parikh RB, Galsky MD, Gyawali B, Riaz F, Kaufmann TL, Cohen AB, Adamson B, Gross CP, Meropol NJ, Mamtani R

February 2019

Abstract

ASCO GU Symposium

February 2019

Abstract

ASCO GU Symposium

February 2019

Abstract

ASCO GU Symposium

February 2019

Abstract

ASCO GU Symposium

February 2019

Abstract

ASCO GU Symposium

Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer

Riaz, F, Presley, CJ, Chiang, AC, Longtine, JA, Soulos, PR, Adelson, KB, Herbst, RS, Nussbaum, NC, Sorg, RA, Abernethy, AP, Agarwala, V, Gross, CP

February 2019

Manuscript

Journal of Geriatric Oncology

Flatiron-authored

January 2019

Abstract

ASCO GI Symposium

January 2019

Abstract

ASCO GI Symposium

January 2019

Abstract

ASCO GI Symposium

January 2019

Manuscript

Advances in Therapy

January 2019

Manuscript

International Journal of Colorectal Disease

January 2019

Manuscript

PLoS One

Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval

Khozin S, Carson KR, Zhi J, Tucker M, Lee SE, Light DE, Curtis MD, Bralic M, Kaganman I, Gossai A, Hofmeister PP, Torres AZ, Miksad RA, Blumenthal GM, Pazdur R, Abernethy AP

December 2018

Manuscript

The Oncologist

Flatiron-authored

December 2018

Abstract

ESMO Immuno-Oncology Congress

December 2018

Manuscript

Current Medical Research and Opinion

Flatiron-authored

Initiation and interruption in intravenous bisphosphonate therapy among patients with multiple myeloma in the United States

McGrath LJ, Hernandez RK, Overman R, Reams D, Liede A, Brookhart MA, O’Donnell E, Leah J

December 2018

Manuscript

Cancer Medicine

Influence of Prognostic Factors on Outcomes Among Metastatic Breast Cancer Patients Treated with CDK4&6 Inhibitors in Routine Clinical Practice

Saverno KR, Carter GC, Li L, Battiato LA, Huang Y-J, Smyth EN, Price GL, Sheffield KM, Baxi SS, Kuk D, Seidman AD

December 2018

San Antonio Breast Cancer Symposium

Flatiron-authored

December 2018

Abstract

San Antonio Breast Cancer Symposium

A real world evidence study of BRCA mutations and survival in HER2-negative breast cancer

Dalvi T, McLaurin K, Briceno J, Nordstrom B, Bennett J, Hettle R, Murphy B, Collins J, McCutcheon S

December 2018

Abstract

San Antonio Breast Cancer Symposium

December 2018

Abstract

San Antonio Breast Cancer Symposium

Real-world survival of heavily pretreated patients with refractory HR+, HER2- metastatic breast cancer receiving single-agent chemotherapy – A comparison with MONARCH 1

Rugo H, Dieras V, Cortes J, Patt D, Wildiers H, O'Shaughnessy J, Zamora E, Yardley DY, Carter GC, Sheffield KM, Li L, Andre VA, Derbyshire RE, Li XI, Frenzel M, Huang Y-J, Dickler MN, Tolaney SM

December 2018

Abstract

San Antonio Breast Cancer Symposium

December 2018

Abstract

Blood Journal

Flatiron-authored

December 2018

Abstract

Blood Journal

Flatiron-authored